Lupin has informed about submission of a press release as regards launch of Clobazam Tablets, 10 mg and 20 mg, being the generic version of Lundbeck Pharms, LLC's Onfi Tablets, 10 mg and 20 mg, indicated for the adjunctive treatment of seizures, for which, US FDA approval was received earlier. This may be considered as a disclosure pursuant to Regulation 30 of the SEW (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
